Medical devices, healthcare technology and the business of care
PMA approval · P140023

COBAS KRAS MUTATION TEST

Roche Molecular Systems, Inc. · Decision date May 7, 2015

MEDTECHLEDGER EXPLANATIONP140023

What did the FDA approve?

FDA’s action here is an approval for PMA P140023 covering the cobas KRAS Mutation Test. The record ties that device to the cobas 4800 System and describes it as a real-time PCR test for detecting seven somatic KRAS mutations in codons 12 and 13 from DNA in formalin-fixed paraffin-embedded human colorectal cancer tumor tissue.

The statement also describes the reported intended use: an aid in identifying CRC patients for whom treatment with Erbitux (cetuximab) or Vectibix (panitumumab) may be indicated when no mutation is detected. It does not provide separate performance data or explain any change to an earlier PMA beyond this approved device scope.

FDA approval order statement

APPROVAL FOR THE COBAS KRAS MUTATION TEST. THIS DEVICE IS INDICATED FOR THE FOLLOWING:THE COBAS KRAS MUTATION TEST, FOR USE WITH THE COBAS 4800 SYSTEM, IS A REAL-TIME PCR TEST FOR THE DETECTION OF SEVEN SOMATIC MUTATIONS IN CODONS 12 AND 13 OF THE KRAS GENE IN DNA DERIVED FROM FORMALIN-FIXED PARAFFIN-EMBEDDED HUMAN COLORECTAL CANCER (CRC) TUMOR TISSUE. THE TEST IS INTENDED TO BE USED AS AN AID IN THE IDENTIFICATION OF CRC PATIENTS FOR WHOM TREATMENT WITH ERBITUX (CETUXIMAB) OR WITH VECTIBIX (PANITUMUMAB) MAY BE INDICATED BASED ON A NO MUTATION DETECTED RESULT.SPECIMENS ARE PROCESSED USING THE COBAS DNA SAMPLE PREPARATION KIT FOR MANUAL SAMPLE PREPARATION AND THE COBAS Z 480 ANALYZER FOR AUTOMATED AMPLIFICATION AND DETECTION.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
May 7, 2015

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P140023
Regulatory pathway
Premarket approval application
Product code
OWD
Decision code
APPR
Decision date
May 7, 2015
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Somatic gene mutation detection system.

Product code
OWD
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P140023 received

    Application receipt date recorded by FDA.

  2. P140023 · FDA decision

    APPR

  3. P140023/S033 · Related supplement

    cobas KRAS Mutation Test

  4. P140023/S034 · Related supplement

    Roche cobas KRAS Mutation Test

Timeline entries are records held by MedtechLedger for P140023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140023

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA

Explore the linked device profile

Other records with product code OWD

Product / regulatory recordCompanyPathwayDecision dateSource
Roche Molecular Systems, Inc.PMA supplementNov 4, 2026FDA
RochePMA supplementNov 4, 2026FDA
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
RochePMA supplementOct 27, 2026FDA
Roche Molecular System, Inc.PMA supplementOct 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Roche Molecular Systems, Inc.

Headquarters
Not reported
Brand website
roche.com
FDA applicant address
4300 Hacienda Dr., Pleasanton, CA, 94588

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records